Most articles on this subject open with an hour-by-hour table. Twenty-four to forty-eight hours, this. Days three to ten, that.
Those tables are more confident than the research they are based on. The three most authoritative sources on methamphetamine withdrawal do not agree on when it starts: one found severity peaking within 24 hours of the last dose, NIDA describes symptoms peaking two to three days after last use, and SAMHSA’s clinical guidance says symptoms begin two to four days after stopping.
What they do agree on is the shape — a sequence of phases that most people move through, with wide individual variation in timing. That is what is actually useful, and it is what follows.
One thing first, because it matters more than any timeline. In the first one to two weeks of withdrawal from stimulants, some people experience suicidal thoughts. SAMHSA’s clinical guidance is direct about it: patients “may experience suicidality and should be monitored appropriately.” If that is happening to you or to someone with you, that is not a phase to wait out alone. In the US, call or text 988 for the Suicide and Crisis Lifeline, or go to an emergency department.
Phase one: the crash
This is the acute phase, and the most consistent finding about it is that it is front-loaded.
The best-documented study followed people through inpatient withdrawal and found overall symptom severity declining from a high initial peak within 24 hours, dropping in a roughly straight line until it was near normal levels by the end of the first week. The acute phase in that study ran seven to ten days.
What it looks like:
- Overwhelming sleep. Not tiredness — a collapse. People sleep enormous stretches.
- Hunger. Appetite returns hard, often after weeks of barely eating.
- A cluster of depression symptoms — flatness, hopelessness, no motivation. This is the most prominent feature of the acute phase, more so than anxiety or craving.
- Agitation and dysphoria, particularly at the front end.
- Intense cravings. SAMHSA notes plainly that these “frequently lead to recurrent substance use.” Most attempts to stop end here, and not because of weak resolve — because this is the point of maximum symptom load.
Sleeping and eating enormously can look, from outside, like nothing much is happening. It is generally the hardest part.
Phase two: the wall
Then things flatten out, and the flatness is the problem.
The postacute phase — clinicians sometimes call it “the wall” — brings profound fatigue, continued heavy sleeping, unstable mood and increased appetite, and can extend two weeks or more beyond the last use. In the McGregor study, once the acute phase ended, most symptoms stayed stable at low levels through the following fortnight.
“Low level” is doing a lot of work in that sentence. What people describe is not acute suffering but an absence: no energy, no interest, no pleasure in anything, a sense that the volume has been turned down on the world. Nothing is unbearable and nothing is good.
This phase is dangerous in a quiet way. The dramatic part is over, everyone assumes the worst has passed, and the person is left with weeks of feeling like a flat grey nothing — with the clear knowledge that one thing would fix it immediately.
Phase three: the long tail
Beyond the first month, symptoms continue to fade, but not evenly and not quickly.
SAMHSA’s guidance is blunt about the main one: “Anhedonia and dysphoria can last for months in people who use MA.” Anhedonia is the inability to feel pleasure — food, music, sex, company, achievement, all registering as neutral. NIDA similarly describes extended withdrawal persisting for months with low mood, anxiety and cravings.
Cravings do not disappear on a schedule either. They typically become less frequent and less consuming, but they can be triggered sharply long after the physical symptoms have gone.
Psychotic symptoms deserve a specific mention. Where they have been present, they can continue into acute withdrawal, and there can be breakthrough psychotic episodes during the protracted phase. Anyone with a history of stimulant-associated psychosis should know that stress and heavy drinking both raise the risk of it recurring.
The month-one trap
There is a phase most timelines leave out entirely, and it catches people.
At around one month, many people experience a genuine lift — euphoria, energy, confidence, a sense that this is over and was easier than expected. SAMHSA’s guidance describes exactly this pattern, and then what tends to follow: depression at three to six months, with high relapse risk.
The lift is real. The conclusion people draw from it — that the work is finished — is what causes the trouble, because it is usually the point at which structure and support get dropped. If you have been through early sobriety before, you may recognize this as the pink cloud, and knowing it is a phase rather than an arrival is most of the protection against it.
Plan for months three to six while month one still feels good.
Is meth withdrawal dangerous?
This needs a careful answer, because the usual one is misleading.
Unlike alcohol or benzodiazepine withdrawal, stimulant withdrawal does not typically produce seizures or life-threatening physical instability. SAMHSA states that “no consistent physiologic disruptions requiring gradual withdrawal have been observed” — there is no need to taper meth the way you must taper a benzodiazepine.
That is frequently translated into “meth withdrawal is safe, you can just stop.” It should not be. The serious risks here are psychiatric rather than cardiovascular:
- Suicidality in the first one to two weeks, which is the reason monitoring is recommended
- Psychosis, where it is already part of the picture
- Severe depression that can outlast the acute phase by months
So the accurate statement is: you are unlikely to be physically harmed by stopping, and the period still warrants supervision. The same SAMHSA guidance notes that while no taper is required, “some medications may attenuate symptoms and provide support and comfort throughout withdrawal.”
What helps
Two facts worth having before you look for help.
There is no approved medication for this. NIDA states it plainly: “there is no FDA-approved medication for methamphetamine use disorder or any other stimulant use disorder.” Anyone promising a medication that treats meth dependence is describing something that does not exist. Medications may be used to help with sleep, agitation or mood during withdrawal, but that is symptom management, not a treatment for the disorder.
The behavioral evidence is real, and one approach leads. Contingency management — structured, tangible incentives for verified periods of abstinence — has the strongest evidence of any treatment for stimulant use disorder.
Beyond that, what the timeline itself argues for is duration. The symptom that most reliably drives return to use — anhedonia — is measured in months, not days. Support that ends when the acute phase ends stops right before the hardest stretch. That is the practical case for residential treatment at a length that covers the long tail rather than just the crash, and for taking seriously what comes after it.
Two other things worth flagging. Depression and anxiety during withdrawal can be withdrawal, or can be an underlying condition that the stimulant use was managing — and the two require different responses, which is what dual diagnosis treatment exists to sort out. And if you are looking at this for someone else, what treatment for methamphetamine addiction involves is a more practical starting point than a symptom list.
The short version
Meth withdrawal is front-loaded and then long. The crash is the worst of it and largely resolves inside seven to ten days. The two to four weeks after that are flat, exhausted and joyless rather than acutely painful, which is its own kind of hard. Anhedonia can persist for months.
Sources disagree on the exact hours, and anyone giving you a precise schedule is giving you more confidence than the evidence supports.
The genuine risks are psychiatric. Suicidal thinking in the first two weeks is common enough that clinical guidance recommends monitoring for it — which is the strongest argument against getting through this alone.
If you’re struggling with stimulant use, you don’t have to work through it alone. Choice House offers residential treatment and sober living for men, with integrated care for co-occurring mental health conditions alongside substance use. Call 720-577-4422 or reach out through our website to talk it through and find out what options might help.
If you are in crisis, call or text 988 (Suicide and Crisis Lifeline) or go to your nearest emergency department.